Evidence map›Paper›PMID 31974614›Full record

ArticleMolecular medicine reports2020

Protein kinase C promotes choline transporter‑like protein 1 function via improved cell surface expression in immortalized human hepatic cells.

Takuya Ishikawa, Hirotsugu Suwanai, Junpei Shikuma, Ryo Suzuki, Tsuyoshi Yamanaka, Masato Odawara, Masato Inazu

Open access · bronzeAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takuya IshikawaDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo 160‑0023, Japan.
Hirotsugu SuwanaiDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo 160‑0023, Japan.
Junpei ShikumaDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo 160‑0023, Japan.
Ryo SuzukiDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo 160‑0023, Japan.
Tsuyoshi YamanakaDepartment of Molecular Preventive Medicine, Tokyo Medical University, Tokyo 160‑8402, Japan.
Masato OdawaraDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo 160‑0023, Japan.
Masato InazuDepartment of Molecular Preventive Medicine, Tokyo Medical University, Tokyo 160‑8402, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choline is used to synthesize phospholipids and a lack of choline induces a number of liver‑related diseases, including non‑alcoholic steatohepatitis. The current study characterized the choline uptake system, at molecular and functional levels, in the immortalized human hepatic cell line, Fa2N‑4, to identify the specific choline transporter involved in choline uptake. The present study also assesed whether choline deficiency or the inhibited choline uptake affected cell viability and apoptosis. Reverse transcription‑quantitative polymerase chain reaction (PCR) revealed choline transporter‑like protein 1 (CTL1) and CTL2 mRNA and protein expression in Fa2N‑4 cells. [Methyl‑3H]choline studies revealed choline uptake was saturable and mediated by a single transport system that functioned in a Na+‑independent but pH‑dependent manner, which was similar to CTL1. Hemicholinium‑3 (HC‑3), which is a choline uptake inhibitor, and choline deficiency inhibited cell viability, increased caspase‑3 and ‑7 activities, and increased fluorescein isothiocyanate‑Annexin V immunofluorescent staining indicated apoptosis. Immunofluorescent staining also revealed CTL1 and CTL2 localized in plasma and mitochondrial membranes, respectively. [Methyl‑3H]choline uptake was enhanced by a protein kinase C (PKC) activator, phorbol‑12‑myristate 13‑acetate (PMA). Immunofluorescence staining and western blot analysis demonstrated increased CTL1 expression on the cell membrane following PMA treatment. The results of current study indicated that extracellular choline is primarily transported via CTL1, relying on a direct H+ gradient that functions as a driving force in Fa2N‑4 cells. Furthermore, it was hypothesized that CTL1 and the choline uptake system are strongly associated with cell survival, and that the choline uptake system is modulated by PKC signaling via increased CTL1 expression on the cell surface. These findings provide further insights into the pathogenesis of liver disease involving choline metabolism.

Indexed as

Antigens, CDApoptosisBiological TransportCaspase 3Caspase 7Cell Line, TransformedCell MembraneCell SurvivalCholineHumansLiverOrganic Cation Transport ProteinsProtein Kinase CRNA, MessengerAntigens, CDCaspase 3Caspase 7CholineOrganic Cation Transport ProteinsProtein Kinase CRNA, MessengerSLC44A1 protein, humancholinecholine deficiencycholine transporterhepatocytesmembrane transport proteinsprotein kinase c

Identifiers

PMID31974614
PMCPMC6947888
OpenAlexW2994914885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.